DNAtrix's Oncolytic Virus Expressing OX40 Ligand Treats First Patient in Recurrent Glioblastoma Clinical Trial

DNAtrix’s Oncolytic Virus Expressing OX40 Ligand Treats First Patient in Recurrent Glioblastoma Clinical Trial (PR Newswire)

UF startup DNAtrix, a leader in oncolytic virus immunotherapies for cancer, announced the treatment of the first patient with DNX-2440, an oncolytic virus expressing OX40 ligand (OX40L). The first-in-human Phase 1 study is evaluating the safety and efficacy of DNX-2440, administered by Alcyone’s Microtip Cannula at the time of biopsy, to patients with recurrent glioblastoma for whom surgery is not possible or planned. DNX-2440 is the second DNAtrix oncolytic adenovirus to advance into the clinic.

DNX-2440 is engineered from DNAtrix’s highly potent oncolytic adenovirus, DNX-2401 (tasadenoturev), which has already demonstrated the ability to selectively kill tumor cells and trigger a powerful immune response directed against the tumor in several clinical studies. In addition to these mechanisms, DNX-2440 expresses OX40L, a critical costimulatory molecule known to enhance antitumor immune responses.

Learn more about DNAtrix’s Oncolytic Virus Expressing OX40 Ligand Treats First Patient in Recurrent Glioblastoma Clinical Trial.

X